Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial

  title={Effect of copper intake on CSF parameters in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial},
  author={H. Kessler and F. Pajonk and D. Bach and T. Schneider-Axmann and P. Falkai and W. Herrmann and G. Multhaup and J. Wiltfang and S. Schaefer and O. Wirths and T. Bayer},
  journal={Journal of Neural Transmission},
  • H. Kessler, F. Pajonk, +8 authors T. Bayer
  • Published 2008
  • Psychology, Medicine
  • Journal of Neural Transmission
  • A plethora of reports suggest that copper (Cu) homeostasis is disturbed in Alzheimer’s disease (AD). In the present report we evaluated the efficacy of oral Cu supplementation on CSF biomarkers for AD. In a prospective, randomized, double-blind, placebo-controlled phase 2 clinical trial (12 months long) patients with mild AD received either Cu-(II)-orotate-dihydrate (verum group; 8 mg Cu daily) or placebo (placebo group). The primary outcome measures in CSF were Aβ42, Tau and Phospho-Tau. The… CONTINUE READING
    43 Citations

    Figures, Tables, and Topics from this paper

    Copper and iron in Alzheimer's disease: a systematic review and its dietary implications
    • 63
    • Highly Influenced
    • PDF
    Copper Modulation as a Therapy for Alzheimer's Disease?
    • 11
    • PDF
    Disturbed Copper Bioavailability in Alzheimer's Disease
    • 30
    • PDF
    Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis
    Anti-copper therapies in Alzheimer's disease: new concepts.
    • 16


    Intake of copper has no effect on cognition in patients with mild Alzheimer’s disease: a pilot phase 2 clinical trial
    • 70
    • PDF
    Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer’s disease
    • 79
    Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease.
    • 75
    Elevation of serum copper levels discriminates Alzheimer’s disease from vascular dementia
    • 49
    Elevation of serum copper levels in Alzheimer’s disease
    • 155
    Copper perturbation in 2 monozygotic twins discordant for degree of cognitive impairment.
    • 28
    • PDF
    CSF markers for Alzheimer's disease: Total tau, phospho-tau and Aβ42
    • N. Andreasen, M. Sjögren, K. Blennow
    • Medicine
    • The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
    • 2003
    • 111
    Zinc and copper modulate Alzheimer Aβ levels in human cerebrospinal fluid
    • 111
    Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
    • 1,261
    • PDF